ArticleMolecular cancer therapeutics2022

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.

Aaron Burmeister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.